[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lbbb\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lbbb":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100617472","left-ventricular-myocardial-work-for-predicting-response-to-crt-100617472",false,"NCT07319065","Left Ventricular Myocardial Work for Predicting Response to CRT","Left Ventricular Myocardial Work for Predicting Response to Cardiac Resynchronization Therapy (CRT): A Multi-Center Study","CARE-MW","Healthy Adults Group\n\nInclusion Criteria:\n\n* Participants must meet all of the following criteria to be enrolled:\n\n  1. Of Han Chinese ethnicity\n  2. Aged 18-79 years\n  3. Normal blood pressure (\\\u003C 140\u002F90 mmHg)\n  4. Normal fasting blood glucose\n  5. Normal blood lipid levels (triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein)\n  6. Normal complete blood count results (hemoglobin concentration, white blood cell count, red blood cell count, platelet count)\n  7. Normal liver and renal function (alanine transaminase \\\u003C 2× upper limit of normal; normal creatinine and blood urea nitrogen)\n  8. Normal electrocardiogram results (occasional atrial premature beats may be enrolled at the investigator's discretion)\n  9. No structural heart disease and normal cardiac function confirmed by echocardiography\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. Clinically significant cardiac valve regurgitation (≥ mild severity)\n2. Respiratory diseases: acute or chronic respiratory disorders\n3. Endocrine diseases: thyroid disease, diabetes mellitus, hyperaldosteronism, pheochromocytoma, etc.\n4. Abnormal liver function (alanine transaminase \\> 2× upper limit of normal), abnormal renal function (elevated creatinine beyond normal range), or dyslipidemia (elevated triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein)\n5. Other systemic diseases: anemia, malignancy, connective tissue disease, large artery\u002Fperipheral vascular diseases (aortic dilation, aortic dissection, coarctation of the aorta, Takayasu arteritis, atherosclerosis), etc.\n6. Pregnant or lactating women\n7. Professional athletes\n8. Poor-quality ultrasound images that cannot support parameter measurement and analysis\n\nHeart failure patients with LBBB who are scheduled for CRT treatment Group\n\nInclusion criteria:\n\n1. LVEF ≤ 35%\n2. QRS ≥ 150ms; LBBB\n3. At least 3 months of optimal drug therapy before implantation\n\nExclusion Criteria:\n\n1. Suffering from connective tissue diseases such as systemic lupus erythematosus, polymyositis, and rheumatoid arthritis;\n2. Having a history of blood diseases and severe systemic diseases such as infections;\n3. Those who cannot cooperate with the examinations.\n\nPatients with LBBB who have preserved LVEF Group\n\nInclusion criteria:\n\n1. LVEF≥53%\n2. LBBB\n\nExclusion Criteria:\n\n1. Suffering from connective tissue diseases such as systemic lupus erythematosus, polymyositis, and rheumatoid arthritis;\n2. Having a history of blood diseases and severe systemic diseases such as infections;\n3. Those who cannot cooperate with the examinations.\n\nPatients with reduced LVEF but without LBBB Group\n\nInclusion criteria:\n\n1. LVEF ≤ 35%\n2. non-LBBB\n\nExclusion Criteria:\n\n1. Suffering from connective tissue diseases such as systemic lupus erythematosus, polymyositis, and rheumatoid arthritis;\n2. Having a history of blood diseases and severe systemic diseases such as infections;\n3. Those who cannot cooperate with the examinations.",true,"ALL","18 Years","79 Years",{"count":22,"type":23},3240,"ESTIMATED","OBSERVATIONAL","This study aims to establish the normal reference values for left ventricular myocardial work in healthy Chinese adults and the influencing factors. Non-invasive myocardial work serves as a new parameter for identifying CRT responders and provides a scoring system for predicting the efficacy of CRT in clinical practice. CRT can improve cardiac function and quality of life, and reduce mortality and hospitalization rates due to heart failure (HF). Currently, the number of CRT treatments is increasing year by year, but even when strictly following the indications, approximately 30% of patients do not respond. Therefore, precise prediction of CRT efficacy is of great clinical significance for improving prognosis. Currently, the indications for CRT mainly rely on clinical, electrocardiogram (CLBBB), and LVEF. By correcting ventricular contraction asynchrony to improve systolic function, however, CLBBB indicates electrical asynchrony, and LVEF improvement depends on mechanical synchrony. If the mechanical asynchrony of the ventricles can be evaluated directly before surgery, it will help predict the efficacy of CRT. Myocardial work is a recently developed non-invasive method that combines LV afterload with the overall longitudinal strain (GLS) analysis of echocardiography. Myocardial work reflects the contraction ability of the heart, stroke work, residual myocardial contraction ability, myocardial oxygen consumption, useless work, useful work, etc., and is represented by the pressure-volume loop analysis, thus having the potential to predict the efficacy of CRT. Therefore, this study intends to adopt the left ventricular myocardial work technique, combined with the current indication criteria, to predict the long-term efficacy of patients with heart failure who are scheduled for CRT treatment, thereby increasing the response rate of CRT and improving the prognosis of patients. Currently, there are no normal reference values for left ventricular myocardial work in healthy Chinese adults. Therefore, our center has initiated this multicenter clinical research project, collaborating with multiple ultrasound centers across the country, aiming to establish the normal ultrasound values for left ventricular myocardial work in healthy Chinese adults, providing new quantitative reference basis for the diagnosis of myocardial function, assessment of the severity of myocardial lesions, and efficacy observation.",[27,28,29,30],"CRT Non-Response","LBBB","HF - Heart Failure","Healthy Adult",[32],"Myocardial work","NOT_YET_RECRUITING","2025-12-21",{"date":36,"type":37},"2026-01-06","ACTUAL",{"date":39,"type":23},"2026-01-01",{"date":41,"type":23},"2027-12-31",{"name":43,"class":44},"First Hospital of China Medical University","OTHER",82,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100489249","left-vs-left-randomized-clinical-trial-100489249","NCT05650658","Left vs Left Randomized Clinical Trial","Cardiac Resynchronization Therapy Using His\u002FLeft Bundle Branch Pacing vs Biventricular Pacing With a Left Ventricular Epicardial Lead in Patients With Heart Failure (HF) With Left Ventricular Ejection Fraction (LVEF)≤50% and With Either a Wide QRS Complex (>130 ms) or With\u002FAnticipated >40% Pacing Randomized Clinical Trial","Inclusion Criteria:\n\n* Men and women 18 years of age or older.\n* A LVEF ≤ 50% within 6 months prior to enrollment.\n* Resting QRS duration ≥130 ms as evidenced by a historical 12-lead ECG prior to enrollment OR anticipated right ventricular pacing \\>40% OR device in place with right ventricular pacing \\> 40%.\n* Are optimized on HF guideline directed medical therapy according to current HF published guidelines OR patient's physician will make an effort to start all guideline-directed medical therapy and titrate doses up as permitted by the participant clinical status and co-morbidities prior to implantation procedure.\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating, or plan to become pregnant during the course of the trial.\n* Participants with angiographic evidence of coronary disease who are candidates for coronary revascularization and are likely to undergo coronary artery bypass graft surgery or percutaneous coronary, intervention in the next three (3) months.\n* Enzyme-positive myocardial infarction within the past three (3) months prior to enrollment.\n* Coronary artery bypass graft surgery or percutaneous coronary intervention (balloon and\u002For stent angioplasty) within the past three (3) months prior to enrollment.\n* Reversible non-ischemic cardiomyopathy (e.g., acute viral myocarditis).\n* Participants with Chagas disease, cardiac sarcoidosis or amyloidosis.\n* Expected to receive left ventricular assist device or heart transplantation within 6 months.\n* Participants with primary severe valvular disease (e.g., aortic stenosis).\n* Have a life expectancy of less than 12 months.\n* Participants with irreversible brain damage from preexisting cerebral disease.\n* Participants with a contrast dye allergy unable or unwilling to undergo pretreatment with steroids and\u002For diphenhydramine.\n* Participants participating in any other interventional cardiovascular clinical trial.\n* Participants who would be unable to comply with the study's follow-up visit schedule; or\n* Participants who had any prior unsuccessful attempt at implantation of biventricular pacing (BiVP), His Bundle Pacing (HBP), or Left Bundle Branch Pacing (LBBP) device.",{"count":54,"type":23},2136,"INTERVENTIONAL",[57],"NA","The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g., lead dislodgement, infection) relative to standard of care biventricular pacing in patients with heart failure due to left ventricular systolic dysfunction (LVEF≤50%) and with either a wide QRS (≥130 ms) or with\u002Fanticipated \\>40% pacing who are already receiving current standard heart failure pharmacological therapy.",[60,61,62,28,63,64,65],"Heart Failure","Heart Failure With Reduced Ejection Fraction","AV Block","RBBB","Intraventricular Conduction Delay","Pacing-Induced Cardiomyopathy","RECRUITING","2025-09-28",{"date":69,"type":37},"2025-10-02",{"date":71,"type":37},"2023-09-13",{"date":73,"type":23},"2029-06-30",{"name":75,"class":44},"Baylor College of Medicine",71]